Related Experiment Video
Updated: Apr 19, 2026
PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
Drug-loaded PLGA-mPEG microparticles as treatment for atopic dermatitis-like skin lesions in BALB/c mice model
Shuibin Feng1, Lei Nie, Peng Zou
1State Key Laboratory of Material Processing and Die & Mould Technology, College of Materials Science and Engineering, Huazhong University of Science and Technology (HUST) , Wuhan , PR China.
Abstract:
This study evaluated the feasibility of mizolastine-loaded microparticles as therapy for atopic dermatitis. Microparticles have been researched for decades as a controlled-release drug delivery system, but seldom been used as treatment for skin disease. In this research, we induced dermatitis in BALB/c mice model by repeated topical application of dinitrofluorobenzene and compared the mizolastine microparticles injection and daily mizolastine injection treatment. The results showed that the mizolastine microparticles treatments significantly inhibited ear thickness and dermatitis index in dermatitis model compared with the dermatitis mice without treatment, showing a similar curative effect compared with daily mizolastine injection treatment, and the improvement continued for several days. Inflammatory cells infiltration into the ears and the plasma level of immunoglobulin E were also suppressed by mizolastine microparticles according to the histopathology analysis. In conclusion, the results suggested that drug-loaded microparticles could be a proper candidate for the treatment of skin diseases.
Insights
Mizolastine microparticles effectively treat atopic dermatitis in mice, reducing inflammation and immunoglobulin E levels. This novel drug delivery system shows promise for treating skin diseases.
Area of Science:
- Dermatology
- Pharmacology
- Nanotechnology
Background:
- Microparticles are established controlled-release drug delivery systems.
- Their application in treating skin diseases remains largely unexplored.
- Atopic dermatitis is a chronic inflammatory skin condition.
Purpose of the Study:
- To evaluate the feasibility of mizolastine-loaded microparticles for treating atopic dermatitis.
- To compare the efficacy of microparticle injections versus daily injections of mizolastine.
- To assess the impact on key inflammatory markers.
Main Methods:
- Atopic dermatitis was induced in BALB/c mice using dinitrofluorobenzene.
- Mice received either mizolastine microparticle injections or daily mizolastine injections.
- Histopathology and immunoglobulin E levels were analyzed.
Main Results:
- Mizolastine microparticles significantly reduced ear thickness and dermatitis index compared to untreated controls.
- The therapeutic effect was comparable to daily mizolastine injections and sustained for days.
- Reduced inflammatory cell infiltration and suppressed plasma immunoglobulin E levels were observed.
Conclusions:
- Drug-loaded microparticles demonstrate potential as a viable treatment for skin diseases.
- Mizolastine microparticles offer a promising therapeutic strategy for atopic dermatitis.
- This approach warrants further investigation for dermatological applications.
